While average proliferative activity (SUVmean) in visceral and combined fat was relatively consistent across tumor subtypes and menopausal status, SUVpeak and SUVmax were significantly elevated in patients with TNBC or ER‐ tumors as compared to those with hormone receptor‐positive/HER2‐positive or ER+ subtypes, respectively (Figure 4). The gene discussed is ERBB2; the disease is neoplasm.